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Abstract
Chronic myeloid leukemia (CML) is caused by the kinase activity of the BCR-Abl fusion protein. The Abl inhibitors imatinib,
nilotinib and dasatinib are currently used to treat CML, but resistance to these inhibitors is a significant clinical problem. The
kinase inhibitor bosutinib has shown efficacy in clinical trials for imatinib-resistant CML, but its binding mode is unknown.
We present the 2.4 A ˚ structure of bosutinib bound to the kinase domain of Abl, which explains the inhibitor’s activity
against several imatinib-resistant mutants, and reveals that similar inhibitors that lack a nitrile moiety could be effective
against the common T315I mutant. We also report that two distinct chemical compounds are currently being sold under the
name ‘‘bosutinib’’, and report spectroscopic and structural characterizations of both. We show that the fluorescence
properties of these compounds allow inhibitor binding to be measured quantitatively, and that the infrared absorption of
the nitrile group reveals a different electrostatic environment in the conserved ATP-binding sites of Abl and Src kinases.
Exploiting such differences could lead to inhibitors with improved selectivity.
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Introduction
Chronic myeloid leukemia (CML) is the result of the constitutive
kinase activity of the tyrosine kinase BCR-Abl, the product of
the bcr-abl gene fusion present on the Philadelphia chromosomes
of patients with CML [1]. Imatinib is a selective inhibitor of
BCR-Abl, and the introduction of imatinib into the clinic
represented a dramatic improvement in CML therapy [2]. The
tyrosine kinases c-Kit and platelet derived growth factor receptor
(PDGFR) are also potently inhibited by imatinib, which is now
used to treat malignancies caused by dysregulated forms of these
proteins [3,4].
Despite the success of imatinib in treating CML, some patients
ultimately develop resistance to imatinib treatment and undergo
clinical relapse [5]. Although bcr-abl gene amplification has been
observed, resistance is most often caused by point mutations in the
kinase domain of BCR-Abl that abrogate the binding of imatinib
[5,6,7]. The emergence of imatinib resistance has led to a search
for additional inhibitors of BCR-Abl, and the second generation
inhibitors dasatinib and nilotinib were recently approved for use in
CML patients resistant to imatinib, as well as for front-line therapy
[8,9].
While dasatinib and nilotinib are active against most imatinib-
resistant BCR-Abl mutations, neither drug is effective against
BCR-Abl bearing the common T315I mutation. Patients that
initially respond to dasatinib therapy and subsequently relapse
have been shown to possess new BCR-Abl mutations, indicating
that clinical resistance to second-generation inhibitors can emerge
[10]. There is therefore continued interest in obtaining additional
Abl inhibitors, both to combat resistance and to broaden the
therapeutic options for CML patients.
Bosutinib is a second-generation dual Abl/Src inhibitor that
exhibits potent growth inhibition of CML cells in vitro, is active
against multiple imatinib-resistant BCR-Abl mutations and has
demonstrated efficacy in ongoing clinical trials for imatinib-
resistant CML [11,12,13]. Bosutinib is devoid of activity against
the receptor tyrosine kinases Kit and PDGFR, and, like other next
generation BCR-Abl inhibitors, is a more potent inhibitor of Abl
than imatinib [11,14]. Due to its activity against the Src kinases,
bosutinib has shown efficacy against several types of cancer in
which Src is implicated [15,16]. Bosutinib is a 4-anilinoquinoline-
3-carbonitrile inhibitor (see Fig. S2A for structure) that is similar in
structure to the drugs erlotinib and gefitinib, inhibitors of the
epidermal growth factor receptor (EGFR). Crystal structures of
other inhibitors of this class bound to kinases have been solved, but
the details of the interaction between bosutinib and Abl are
unknown. In the course of studies of electrostatic interactions in
the ATP-binding sites of several kinases, briefly outlined at the end
of this report, we determined the crystal structure of the kinase
domain of Abl bound to bosutinib at 2.4 angstrom resolution. The
structure explains the effects of imatinib resistance mutations on
bosutinib binding, and provides a basis for interpreting spectro-
scopic measurements that probe the environment of the ATP-
binding site of Abl and other kinases.
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Protein purification and crystallization
The kinase domains of wild-type human c-Abl (residues 229–
512) and wild-type and T338I human c-Src (residues 254–536)
were expressed in E.coli BL21 (DE3) (Invitrogen) and purified by
affinity, ion exchange and gel filtration chromatography as
previously described [17]. Extensive previous work has demon-
strated that Abl expressed in bacteria is correctly folded and
retains catalytic activity [17,18,19,20]. Samples of the Abl:bosu-
tinib and Abl:bosutinib isomer complexes were prepared by
mixing Abl kinase domain (in sample buffer: 50 mM Tris-HCl
pH 8.0, 150 mM NaCl, 2 mM DTT) with a three-fold excess of
bosutinib (Tocris Bioscience) or bosutinib isomer (LC Labs) in
DMSO and performing buffer exchange with sample buffer to
remove the DMSO and unbound drug. Sparse matrix screening
was used to identify conditions conducive to crystallization.
Crystals were obtained in 0.1 M Ammonium Acetate, 0.1 M
MES pH 5.5 and 11% PEG 10 K, and cryo-protected in the same
condition plus 30% glycerol.
Kinase assays
Kinase activity was measured using a coupled kinase assay in
which the production of ADP is linked to the oxidation of NADH
by pyruvate kinase and lactate dehydrogenase [17]. Assays were
performed in 75 ml reactions containing 100 mM Tris-HCl
pH 8.0, 10 mM MgCl2, 2 mM ATP (Sigma Aldrich), 0.5 mM
Abltide substrate peptide (Anaspec), 1 mM phosphoenolpyruvate
(Sigma Aldrich), 0.6 mg/ml NADH (Sigma Aldrich), 1 mM DTT,
and 50 nM Abl kinase. The measurements were corrected for
background activity in the absence of substrate peptide.
X-ray data collection and refinement
X-ray diffraction data were collected at the Stanford Linear
Accelerator Center on beamlines 12-2 and 7-1. Data were
processed with mosflm [21] and CCP4 [22]. The structure of
Abl bound to the bosutinib isomer was solved by molecular
replacement in Phenix [23] using the structure of Abl bound to
VX-680 [24](pdb code 2F4J) as a search model. Model rebuilding
was performed with Coot [25] and refinement with Phenix. For
the structure of Abl bound to authentic bosutinib, the R-free flags
used in refinement were copied from the bosutinib isomer dataset,
and the refined model of Abl bound to the bosutinib isomer was
used with only limited refinement. To confirm the positions of the
chlorine atoms on the aniline ring of bosutinib we exploited the
anomalous scattering of chlorine. While the chlorine K absorption
edge is near that of sulfur at ,2800 eV (4.4 A ˚), chlorine and sulfur
both retain significant anomalous scattering at shorter wavelengths
[26]. Using synchrotron radiation at a wavelength of 1.76
angstroms, the longest wavelength accessible on beamline 7-1 at
the Stanford Synchrotron Radiation Laboratory, we collected a
highly redundant dataset to a resolution of 2.9 angstroms on a
crystal of the Abl:bosutinib complex (Table 1). Anomalous
difference maps calculated from this data using the phases from
the refined 2.4 angstrom structure showed strong peaks (,5
standard deviations above the mean) for many of the sulfur atoms
in the protein, as well as the four chlorine atoms of the two
bosutinib molecules in the asymmetric unit.
Fluorescence binding assays
Abl and Src kinase domain (5 nM) were mixed with different
concentrations of bosutinib in 20 mM Tris-HCl pH 8.0, and the
fluorescence emission was monitored at 480 nm, with excitation at
either 280 nm or 350 nm. For the T338I mutant of Src the
fluorescence emission intensity was plotted as a function of the
bosutinib concentration and fit to a single binding site model
(Graphpad Prism) to obtain the equilibrium dissociation constant.
For wildtype Abl and Src the binding is too tight to determine in
this manner. Instead, the titrations were fit directly to the
analytical solution to the one-to-one binding equilibrium using
Mathematica (Wolfram Research).
Like bosutinib, vandetanib exhibits a strong increase in
fluorescence on binding to Src and Abl. Binding curves, where
the emission intensity at 440 nm (with excitation at 280 nm) was
plotted as a function of the total vandetinib concentration, were fit
to a single binding site model with Graphpad Prism.
To measure bosutinib binding to phosphorylated Abl, Abl
kinase domain (100 mM) was phosphorylated with Hck kinase
domain (5 mM), in 2 mM ATP, 10 mM MgCl2, 20 mM Tris-HCl
pH 8.0 and 10% glycerol, for 5 hours at room temperature, and
phosphorylation was verified by mass spectrometry. Experiments
were performed in parallel with the phosphorylated and unpho-
sphorylated samples.
Infrared spectroscopy
Samples of the kinase:inhibitor complexes were prepared by
mixing kinase in buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl,
2 mM DTT, 10% glycerol) and inhibitor stocks in DMSO to a
final DMSO concentration of 5% and concentrating the samples
to ,2 mM. Due to the very tight binding as well as the very low
aqueous solubility of the inhibitors, the concentration of free
ligand in these samples was negligible. Samples were loaded into a
sample cell with ,100 mm path length and infrared spectra were
measured using a Vertex FTIR spectrometer (Bruker).
The linear Stark tuning rate of the nitrile goup of bosutinib and
the bosutinib isomer were determined as described previously
[27]. Briefly, the compounds were dissolved in 1-propanol at
50 mM concentration and loaded into a custom sample cell
consisting of nickel-coated sapphire windows. Samples were flash-
frozen in a custom-built liquid nitrogen immersion cryostat [28],
and a high voltage power supply was used to apply an external
electric field across the sample. Stark spectra are the difference in
the absorbance spectra with the applied field on and off, which
were each determined from the average of 128 scans of the
interferometer mirror. The linear Stark tuning rate was deter-
mined from a numerical fit of the derivatives of the absorbance to
the Stark spectrum.
NMR spectroscopy
Samples of bosutinib (Tocris Bioscience) and the bosutinib
isomer (LC Labs) were dissolved in DMSO-d6 to a concentration
of 20 mM. 1-dimensional proton and carbon spectra and 2-
dimensional
1H-
13C Heteronuclear Single Quantum Coherence
(HSQC) experiments were recorded on 500 and 600 MHz NMR
spectrometers.
Accession numbers
Structure factors and the coordinates of the Abl:bosutinib
structure have been deposited in the Protein Data Bank (http://
www.rcsb.org) with accession number 3UE4.
Results and Discussion
Identification of a reliable commercial source of
bosutinib
The kinase domain of human Abl was expressed in bacteria,
and purified to homogeneity. Kinase assays demonstrated that, as
previously reported, the bacterially expressed protein is catalyti-
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of ‘‘bosutinib’’ obtained from the company LC Labs (also known
as PKC Pharmaceuticals), and solved the structure by molecular
replacement to 2.9 angstroms resolution (Table 1). During the
course of the refinement of this structure we noticed a peculiar lack
of electron density for the 2-chloro atom on the aniline ring of the
small molecule, which called into question the identity of the
compound (Figure 1A). A series of NMR experiments demon-
strated that two different isomers, that differ in the position of
substituents on the aniline ring, are being sold under the name
‘‘bosutinib’’ by different vendors, and that the compound initially
used was, in fact, an isomer of bosutinib. These experiments are
discussed in detail in the Supporting Information (Figure S2), and
a brief description is given below.
Mass spectrometry showed that the compounds from both
commercial sources had the expected mass of m/z 530.1 (M+1).
While the proton NMR spectra of the compound sold by Tocris
Bioscience precisely matches that reported for bosutinib by the
research group at Wyeth that developed the drug [29], the
spectrum of the compound sold by LC Labs is significantly
different in the aromatic region (Figure 1B). Multidimensional
NMR experiments on the LC Labs compound (Figure S2)
indicated the presence of C2 symmetry on the aniline ring, which
is incompatible with the chemical structure of bosutinib, and
suggested that the positions of the substituents on the aniline ring
(two chlorine atoms and a methoxy group) were what differed
between the two compounds.
Crystals of Abl kinase domain bound to the compound from
Tocris Bioscience were obtained in the same crystal form, and we
solved the structure to a resolution of 2.4 angstroms (Table 1). A
simulated annealing omit map shows excellent electron density for
the drug, with the aniline ring clearly resolved (Figure 1C).
However, because the chlorine atoms and methoxy group on the
aniline ring each possess 17 electrons, the x-ray scattering from
these groups is similar, and at the resolution of this structure they
cannot be distinguished from each other. To conclusively
demonstrate that these substituents were correctly positioned on
the aniline ring, we exploited the anomalous scattering of chlorine.
X-ray diffraction data were collected using a synchrotron x-ray
wavelength of 1.76 angstroms, where the anomalous scattering of
chlorine is significant (Table 1) [26]. Anomalous difference maps
calculated using the phases from the refined molecular model
show strong peaks (greater than 4 standard deviations above the
mean) for the chlorine atoms of the drug in the ortho and para
positions on the aniline ring, confirming the identity of the
compound (Figure 1C).
We refer to the correct compound as ‘‘bosutinib’’ and to the
incorrect one as the ‘‘bosutinib isomer’’. To date the protein
databank contains two entries for ‘‘bosutinib’’, bound to calcium
calmodulin regulated protein kinase II and to serine threonine
kinase 10. The title of the latter entry states that the compound
was modified by radiation damage, and the pdb coordinates (pdb
code 3ZZ2) show that the 2-chloro atom on the aniline ring is
missing, and a chlorine atom is instead located in the meta
position. Given the fact that the affected atom is the same one that
is missing in our bosutinib isomer, a likely possibility is that the
authors were afflicted by the same problem we have encountered.
Interestingly, the
1H NMR spectrum of our bosutinib isomer is
very similar to the NMR spectrum reported in a paper describing
an alternative synthesis for bosutinib [30]. These observations
raise the prospect that this problem is widespread, with multiple
vendors selling the incorrect isomer of bosutinib.
The structures of Abl bound to the two different compounds
are almost identical, although the bosutinib complex exhibits
considerably lower temperature factors, and the amino acid side
chains in contact with the small molecule are better resolved
in the bosutinib complex. All spectroscopic measurements
reported in this work were performed on both compounds. Below
we focus on the data obtained with authentic bosutinib; further
results with the incorrect isomer can be found in the supporting
information.
Table 1. Data collection and refinement statistics.
Data Collection Abl:bosutinib isomer Abl:bosutinib Abl:bosutinib (anomalous)
X-ray wavelength (A ˚) 0.98 0.98 1.76
Space group P22121 P22121 P22121
Unit cell dimensions (A ˚) 57.3,113.6,128.4 56.9,113.8,127.6 57.3,113.6,128.4
Resolution range (A ˚) 28-2.9 63-2.4 63-2.9
Rsym
a 0.144 (0.657) 0.112 (0.552) 0.128 (0.579)
Average I/s(I)
a 8.8 (2.6) 13.5 (3.1) 15.7 (5.2)
Completeness
a 97.4% (98.9%) 93.8 (94.8) 99.3 (98.5)
Redundency 4.1 5.9 13.7
Refinement
Number of reflections 18388 30158
Rwork/Rfree 0.178/0.260 0.188/0.249
# of protein atoms 4350 4306
# of ligand atoms 130 130
# of solvent atoms 79 152
RMSD Bond lengths (A ˚) 0.008 0.008
Bond angles (u) 1.112 1.059
avalues in parentheses are for the highest resolution shell.
doi:10.1371/journal.pone.0029828.t001
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Abl or Src kinases
In the course of studying the interaction between bosutinib and
the kinases Src and Abl, we discovered that the inhibitor becomes
strongly fluorescent upon binding to these proteins, a property that
could be of general utility for measuring inhibitor binding. Both
bosutinib and the bosutinib isomer possess an absorption band at
350 nm, and excitation of the free ligand at 350 nm results in
weak fluorescence emission at 480 nm. Upon binding to Src or
Abl, the fluorescence intensity at 480 nm increases ,10 fold. In
the case of the bosutinib isomer the background fluorescence of
the free compound is even lower, and the relative increase in
fluorescence on binding is ,500 fold. Interestingly, for both
compounds, excitation of the protein:inhibitor sample at 280 nm
also results in strong fluorescence emission at 480 nm. A titration
of bosutinib with excitation at 280 nm results in quenching of
tryptophan fluorescence at 340 nm and a rise in emission at
480 nm, indicating that Fo ¨rster resonance energy transfer (FRET)
occurs between the protein and bosutinib (Figure 1D).
The increase in inhibitor fluorescence upon binding affords a
convenient assay for quantifying inhibitor binding, which we used
to measure the binding constants of bosutinib for Src and Abl
kinases. Because the minimum concentration of fluorescent
protein:ligand complex that can be reliably measured on our
fluorimeter is ,1 nM, and the binding is considerably tighter than
this, the titration curves were fitted using a numerical fitting
procedure that accounts for ligand depletion (Figure 1D inset, see
Materials and Methods for the fitting procedure). The binding
constants for Src and Abl are both ,200 picomolar.
Interactions between bosutinib and Abl
The asymmetric unit of our structure contains two copies of the
Abl: bosutinib complex (labeled A and B in the molecular model),
which are almost identical, and only complex B will be discussed.
Bosutinib occupies the ATP-binding site of Abl, sandwiched
between the N-terminal and C-terminal lobes of the kinase. The
binding mode is very similar to that observed with the chemically
related inhibitors gefitinib and erlotinib bound to EGFR [31,32],
with the quinoline group of bosutinib oriented in almost identical
fashion to the quinazoline groups of the EGFR inhibitors, except
for a slight rotation of the quinoline plane to accommodate the
nitrile group, which would otherwise clash with the sidechain of
T315 (Figure 2A). The only hydrogen bond formed between
bosutinib and Abl is between the quinoline N1 nitrogen atom and
the backbone amide of M318 (a residue in the hinge region of the
kinase), a characteristic feature of the binding mode of this class of
inhibitors. The 2,4-dichloro-5-methoxy aniline fragment of
bosutinib is oriented at a ,65u angle to the plane of the quinoline
Figure 1. Identification of two different isomers of bosutinib. A) View of the ligand from our initial structure of Abl bound to the bosutinib
isomer. The ligand is shown as sticks, colored according to the temperature factors (B-factors) of the atoms, with blue indicating low B-factors and red
indicating high B-factors. The 2Fo-Fc electron density map, calculated with phases derived from a refined molecular model that included the 2-chloro
group of bosutinib, is shown as a blue mesh. B)
1H NMR spectra of bosutinib (Tocris Bioscience, blue) and the bosutinib isomer (LC Labs, red),
showing only the aromatic region. C) View of the ligand from our structure of Abl bound to authentic bosutinib. The coordinates of bosutinib are
shown as blue sticks. A simulated annealing omit map contoured at 0.8 standard deviations above the mean (0.8s) is shown as a blue mesh. An
anomalous difference map, contoured at 3.0s, is shown in red. D) Fluorescence emission spectra (excitation at 280 nm) of 50 nM Abl kinase domain
in the presence of varying concentrations of bosutinib (the spectra are colored according to bosutinib concentration, which was varied in 10 nM
increments from 0 nM shown in blue to 60 nM shown in red). The inset shows a binding curve measured for 5 nM Abl. The normalized fluorescence
intensity at 480 nm is plotted as a function of the total bosutinib concentration. The smooth line shows the numerical fit (see Materials and Methods).
doi:10.1371/journal.pone.0029828.g001
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projecting from the N-lobe into the ATP-binding site. The flexible
N-propoxy-N-methylpiperazine group is well ordered in our
structure and extends out of the ATP-binding site, where it makes
van der Waals contacts with the kinase hinge region.
Of the three BCR-Abl inhibitors currently approved for clinical
use, the interaction of bosutinib with Abl is most similar to that of
dasatinib [33], but in the deepest portion of the ATP-binding site
there are notable differences. In the dasatinib cocrystal structure
an amide group on dasatinib forms a hydrogen bond to the
Figure 2. Structure of authentic bosutinib bound to the Abl tyrosine kinase domain. A) Interaction of bosutinib (blue) with the hinge
region of Abl (yellow). For comparison, the binding modes of erlotinib (red) and gefitinib (pink) are also shown, and were obtained by aligning the
structures of these compounds bound to EGFR (pdb codes 1M17 and 2ITY for erlotinib and gefitinib, respectively) on the hinge region of Abl. B) The
interactions between bosutinib and T315 and V299 of Abl are shown. The residues T315 and V299 are shown as sticks and a yellow surface, and
bosutinib is shown as blue sticks, with the 2Fo-Fc electron density map shown as a blue mesh. The T315I mutation is modeled as thin black sticks, and
the resulting clash with bosutinib is shown as black dots. C) Binding curves for bosutinib binding to Src and the Src T338I mutant. The fluorescence
intensity measured at 480 nm is plotted as a function of the total bosutinib concentration. The inset shows an expanded view of the binding curve
for Src. The equilibrium dissociation constants were determined by a fitting procedure described in the Materials and Methods. D) Binding curves for
vandetanib binding to Abl, Src and the Src T338I mutant. The fluorescence emission intensity measured at 440 nm, with excitation at 280 nm, is
plotted as a function of the total vandetanib concentration. E) The conformation of the P-loop in our structure (shown in yellow, the two disordered
residues are indicated as a dashed yellow line), compared to that observed in the imatinib cocrystal structure (pdb code 1IEP, shown in gray), and a
substrate complex of Abl (pdb code 2G1T, shown in brown). The clash between Y253 and bosutinib that would result from the collapsed
conformation of the P-loop is shown as black dots.
doi:10.1371/journal.pone.0029828.g002
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occupies the same space as the amide of dasatinib, but is at an
angle incompatible with a hydrogen bond and makes only van der
Waals contacts with T315. The aniline substituent of bosutinib is
bound in a similar orientation as the 2-chloro-6-methyl phenyl
group of dasatinib, but displaced ,2 angstroms further out of the
ATP-binding site towards the phosphate-binding loop. There is
thus a cavity where the 2-chloro-6-methyl phenyl ring of dasatinib
would reside, which is filled by an ordered water molecule in the
bosutinib complex.
Implications for the activity of bosutinib against imatinib-
resistant BCR-Abl mutants
The interactions between bosutinib and the ATP-binding site of
Abl explain the effect of several imatinib-resistance mutations on
bosutinib binding [34]. The sidechain of T315 is completely
enveloped by bosutinib, making extensive van der Waals contacts
with both the nitrile group and the 5-methoxy group of the aniline
ring (Figure 2B). The nitrile group is also in van der Waals contact
with the sidechain of V299. Both the T315I and V299L mutations
would result in steric clashes with bosutinib, explaining why these
mutations confer resistance to bosutinib [34]. We used our
fluorescence binding assay to measure the binding constant for the
gatekeeper mutant of Src (T338I), which, unlike the T315I mutant
of Abl, expresses well in bacteria, and found that the binding is
much weaker than for wildtype Src, with a KD value of ,250 nM
(Figure 2C).
Despite the extent of the contacts between T315 and bosutinib,
modeling indicates that the only clash that results between
bosutinib and the isoleucine residue of the T315I mutant is with
the nitrile group, suggesting that the drug could be accommodated
by this mutant if the nitrile group were missing (Figure 2B). Thus
the binding of 4-anilinoquinazolines, which are similar to
bosutinib but lack the nitrile group, should not be impeded by
the T315I mutation. Indeed, in a screen of inhibitors against a
large panel of kinases the 4-anilinoquinazolines erlotinib and CI-
1033 inhibited wildtype Abl and the T315I mutant with similar
KD values [35]. To further test this hypothesis, we used our
fluorescence binding assay to measure the binding of the 4-
anilinoquinazoline vandetanib, a drug that is used in the treatment
of medullary thyroid cancer, caused by dysregulated RET tyrosine
kinase [36]. Indeed, we found that vandetanib inhibits Abl, Src,
and the Src T338I mutant with very similar KD values of
,100 nM (Figure 2D).
While these 4-anilinoquinazolines inhibit Abl too poorly to be
effective in cells, where they must compete with high concentra-
tions of ATP for binding to the kinase, other 4-anilinoquinazolines
could prove effective against the T315I mutation. It is interesting
to note that, during the treatment of cancers caused by
dysregulated EGFR with 4-anilinoquinazoline inhibitors, clinical
resistance is caused by mutation of the gatekeeper threonine
residue to methionine [37], but that this mutation exerts its effect
not through steric hindrance, but through lowering the KM value
for ATP [38]. It appears that the inclusion of the nitrile group in
bosutinib, which improves the potency against wildtype Src kinase
relative to the corresponding quinazoline [39], inadvertently made
the inhibitor highly susceptible to resistance mediated by mutation
of the gatekeeper residue.
Our structure also explains the ability of bosutinib to override
imatinib resistance mutations that map to the phosphate-binding
loop (P-loop), a loop involved in binding the phosphates of ATP. It
has been argued that these P-loop mutations exert their effects by
destabilizing the conformation of the P-loop favored by imatinib,
in which the loop collapses to form a hydrophobic cage that
envelops the drug [6,40,41]. Structures of Abl bound to other
kinase inhibitors have shown similar collapsed P-loop conforma-
tions [24,42], suggesting that the P-loop of Abl is particularly
susceptible to conformational changes induced by the binding of
inhibitors. In our structure of Abl bound to bosutinib two residues
at the tip of the P-loop (Q252 and Y253) are poorly ordered, but
the remainder of the loop adopts an extended conformation
similar to the b-hairpin observed in a substrate complex of Abl
[43] and makes no contacts with bosutinib (Figure 2E). Aligning
the structure of Abl in complex with imatinib onto our structure
reveals that the collapsed conformation of the P-loop is
incompatible with bosutinib binding, as it would produce a clash
between the sidechain of Y253 and the 6-methoxy group of
bosutinib (Figure 2E). In an in vitro study of the effect of imatinib
resistance mutations on inhibition by dasatinib, nilotinib and
bosutinib, bosutinib was not affected by either the Q252H or
Y253F mutations [34], consistent with the lack of interactions
between bosutinib and the P-loop.
The DFG motif adopts an inactive conformation in our
structure
The kinase inhibitor imatinib binds to an inactive conformation
of Abl in which the aspartate and phenylalanine residues of the
catalytically important Aspartate-Phenylalanine-Glycine (DFG)
motif exchange positions (called the DFG-Out conformation, in
contrast to the active DFG-In conformation) [40,42]. In contrast,
several crystal structures, including structures of gefitinib and
erlotinib bound to EGFR, have demonstrated that 4-anilinoqui-
nazoline inhibitors usually bind to the active conformations of
protein kinases [31,32]. In our structure of Abl bound to bosutinib,
the DFG motif is in an inactive DFG-Out conformation, but this
conformation is distinct from the DFG-Out conformation
observed in complex with imatinib. In the structure of Abl bound
to imatinib, the activation loop undergoes a dramatic rearrange-
ment from the active conformation in which the C-terminal
portion of the loop blocks the active site, resulting in a ,4A ˚ shift
of the DFG motif nearer to the front of the active site. In our
structure the overall conformation of the activation loop is instead
similar to that observed in active kinases, except for the
conformation of the DFG motif itself, as well as a single-residue
shift in the register of the short b–sheet in the N-terminal portion
of the loop (residues 383–386). This conformation of the activation
loop has been observed previously in structures of Abl bound to
the kinase inhibitors PD16 and PD17 [42,43,44]. Bosutinib makes
only very limited contact with the activation loop in our structure,
and aligning the structure of Abl bound to dasatinib onto our
structure suggests that both conformations of the DFG motif are
equally well accommodated by bosutinib (Figure 3A). The
aspartate residue of the DFG motif is protonated in the DFG-
Out conformation, and low pH has been shown to stabilize the
DFG-Out conformation of Abl [45]. The fact that our crystals of
the Abl:bosutinib complex were obtained at pH 5.5, combined
with the absence of phosphorylation on the activation loop - a
posttranslational modification that stabilizes the activation loops of
many kinases in the active conformation [46,47] - likely explains
the DFG-Out conformation observed in our structure.
Phosphorylation on Tyr 393 in the activation loop of Abl
stabilizes the DFG-In conformation (Figure 3A), and severely
interferes with the binding of imatinib, which binds exclusively to
the DFG-Out conformation of Abl [40]. To test whether bosutinib
can bind to the active conformation of Abl, in addition to the
DFG-Out conformation observed in our structure, we measured
the binding of bosutinib to Abl that was phosphorylated on the
activation loop. Abl kinase domain was phosphorylated using
Structure of Bosutinib Bound to Abl
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e29828catalytic amounts of the Src kinase Hck [40]. The binding
constant of bosutinib for phosphorylated Abl was indistinguishable
from unphosphorylated Abl (Figure 3B). This indicates that
bosutinib, unlike imatinib, can bind to the DFG-In conformation
of Abl as well as the DFG-Out conformation of Abl observed in
the structure. Apparently, like other next-generation BCR-Abl
inhibitors, bosutinib binds to the kinase domain of Abl with less
stringent conformational requirements than imatinib, an observa-
tion that has been used to explain the higher affinity of these
compounds.
The nitrile group of bosutinib affords a sensitive
vibrational probe of the local environment in the ATP-
binding site
While the kinase domains of Abl and Src share ,48% sequence
identity, the residues projecting into the ATP-binding site are
completely conserved between the two proteins. High sequence
conservation of the ATP-binding site is characteristic of protein
kinases and contributes to the difficulty of developing selective
kinase inhibitors [48].
We wondered how similar Src and Abl actually are in terms of
the physical environment of the ATP-binding site. The nitrile
group of bosutinib happens to possess favorable properties for
addressing this question, as its vibrational absorption occurs in a
region of the infrared spectrum that is uncluttered by contributions
from protein groups and is highly sensitive to the local electric field
through the vibrational Stark effect [27].
The vibrational Stark effect allows shifts in the absorbance of a
vibrational probe, D  n n, to be related to changes in the projection of
the local electric field along the probe axis, D~ F Fprotein, through the
relationship hcD  n n~{D~ m mprobe:D~ F Fprotein, where h is Planck’s
constant, c is the speed of light and D~ m mprobe is the linear Stark
tuning rate of the vibrational probe. To calibrate the sensitivity of
the bosutinib nitrile to electric fields we performed vibrational
Stark spectroscopy measurements, where the linear Stark tuning
rate is determined by applying an external electric field across the
sample and measuring the effect on the vibrational absorption
(Figure 4A) [27]. The linear Stark tuning rate of bosutinib is
0.87 cm
21/(MV/cm), which is similar to the value for other
aromatic nitriles [27,49]. Mutations in proteins have been shown
to result in changes in electric field as large as 10–20 MV/cm,
producing peak shifts of nitrile probes of up to 15 cm
21, which can
be routinely measured [50,51].
We measured the vibrational absorption of bosutinib when
bound to the kinase domains of Abl, Src, and the Src T338I
mutant using fourier transform infrared (FTIR) spectroscopy
(Figure 4B). The nitrile stretching band of bosutinib is very similar
when bound to Abl and Src, although a shoulder in the Abl
spectrum complicates the determination of the precise peak
position. In contrast, the nitrile band is shifted ,7c m
21 to the red
in the case of the Src T338I mutant. This shift corresponds to a
difference in electric field of 8 MV/cm or 3 kT/eA ˚, indicating
that the nitrile group experiences a completely different environ-
ment in this mutant. A possible explanation for this observation is
that the mutation of the gatekeeper removes a repulsive
electrostatic interaction between the nitrile group and the
sidechain hydroxyl group of the gatekeeper. A change in the
binding mode of the drug is also a possible explanation, although it
should be noted that while bosutinib binds the T338I mutant
much more weakly than wildtype Src, it still binds with nanomolar
affinity (see Figure 3B) and the binding mode is likely similar.
We also measured the nitrile vibrational frequency of the
bosutinib isomer, which possesses a similar linear Stark tuning rate
to bosutinib (Figure S3), bound to Abl and Src (Figure 4C). For
this compound both IR spectra display single peaks in the nitrile
stretch region, and the high quality of the spectra allows the peak
positions to be determined to within ,0.1 cm
21. The nitrile bands
differ by 1.1 cm
21, corresponding to a difference in electric field
experienced by the nitrile of 1.4 MV/cm or 0.6 kT/eA ˚. This
difference in the field can be directly converted into a measure of
how favorable the electrostatic environment of the ATP-binding
site is for the nitrile group of the bosutinib isomer. Nitrile groups
possess a dipole moment of ,2–4 Debye or 0.4–0.8 eA ˚, and the
difference in field of 0.6 kT/eA ˚ translates into a difference in
electrostatic energy of 0.25–0.5 kT for the nitrile group of
bosutinib in Src and Abl, indicating that the electrostatic
environment is slightly more favorable for the nitrile in Src than
in Abl.
While this difference is relatively small, it is nonetheless on a
scale that is energetically significant, which is remarkable given
that identical residues make up the ATP-binding sites of Src and
Abl (Figure 4D). Assuming such differences are representative of
Figure 3. Bosutinib binds to both DFG-In and DFG-Out Abl. A) Comparison of the conformation of the activation loop and DFG motif in our
structure (DFG-Out, yellow) and in the dasatinib cocrystal structure (DFG-In, gray). The sidechains of D381 in the dasatinib structure and F382 in our
structure, which occupy very similar positions, are shown as spheres. Bosutinib is shown as sticks and spheres. The position of the phosphate group
on the phosphorylated sidechain of Y393 in the dasatinib structure is shown as an orange sphere. B) Binding curves for bosutinib binding to Abl and
to Abl phosphorylated on the activation loop (Abl-pY393).
doi:10.1371/journal.pone.0029828.g003
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inhibitor with optimal electrostatic properties could possess
significant selectivity between Src and Abl, despite the conserva-
tion of their ATP-binding sites. It will be interesting to see the
extent to which the environment of the ATP-binding site varies
across more distantly related protein kinases, and we are now
pursuing experiments to address this.
Conclusion
Clinical resistance to kinase inhibitors is currently the primary
problem facing the treatment of CML. Our structure explains the
activity of bosutinib against imatinib resistant mutants of Abl, and
should help to rationalize patterns of resistance that may yet
emerge from the use of bosutinib in the clinic. While bosutinib, like
the three currently approved inhibitors of BCR-Abl, is inactive
against the common T315I mutation, our results suggest that the
related 4-anilinoquinazolines are not affected by this mutation,
and might yield an effective remedy for this form of BCR-Abl.
The high degree of sequence conservation in the ATP-binding
sites of protein kinases hampers the development of selective
kinase inhibitors. We have shown that nitrile-bearing inhibitors
like bosutinib and the bosutinib isomer can be used to study
electrostatic differences in the ATP-binding sites of kinases. The
closely related kinases Src and Abl have identical ATP-binding site
sequences, but nonetheless display distinct electrostatics. More
distantly related kinases are likely to have much larger differences
in electrostatics, and a thorough understanding of such differences
might allow for the rational design of selective inhibitors whose
electrostatic properties are tailored to the electrostatics of the ATP-
binding site they are intended to bind.
Supporting Information
Figure S1 Activity of bacterially expressed Abl kinase
domain. Bacterially expressed Abl is catalytically active and
inhibited by imatinib. Kinase activity was measured using a
coupled kinase assay in which the production of ADP by the kinase
is linked to the oxidation of NADH by pyruvate kinase and lactate
dehydrogenase
1.
(DOC)
Figure S2 NMR experiments on bosutinib and the
bosutinib isomer. A) The structure of bosutinib and a putative
structure for the bosutinib isomer are shown. The blue numbers
on the bosutinib structure represent the five aromatic proton-
carbon pairs. The numbers on the aniline ring of the bosutinib
isomer are
13C chemical shifts. B) NMR spectra. In the top left
panel,
1H-
13C HSQC spectra of bosutinib and the bosutinib
isomer are shown. The thick black lines connect the peaks that
arise from the equivalent proton-carbon pairs in the two
compounds. The thin gray lines are intended to guide the eye to
the corresponding peaks in the 1-dimensional spectra. The peaks
for the five aromatic proton-carbon pairs in authentic bosutinib
are indicated with large blue numbers. These putative assignments
are based on
13C chemical shift predictions. The bottom panel
Figure 4. The nitrile group of bosutinib and the bosutinib isomer probe electrostatics in the ATP-binding site. A) Infrared absorbance
(top) and Stark (bottom) spectra of 50 mM bosutinib in 1-propanol, measured at 77 K. A numerical fit to the Stark spectrum, from which the linear
Stark tuning rate was derived, is shown in red. The numerical fit is a weighted sum of the derivatives of the absorption spectrum, and the individual fit
components are shown as thin lines. B) The nitrile stretch region of infrared absorbance spectra of bosutinib bound to the kinase domains of Abl
(black), Src (red) and the Src T338I mutant (blue). C) Infrared spectra of the bosutinib isomer bound to Abl (black) and Src (red). D) The residues that
comprise the ATP-binding site near the nitrile of bosutinib (black) are shown for our structure of Abl bound to bosutinib (yellow) and for that of Src
bound to dasatinib (pdb code 3G5D, dark red).
doi:10.1371/journal.pone.0029828.g004
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1H NMR spectra of both compounds. The peak located
at 7.34 ppm in the bosutinib isomer sample, which integrates to 2,
is indicated. The colored numbers directly next to the peaks are
the peak integrations. The panel on the upper right shows the
aromatic region of the
13C NMR spectrum of the bosutinib
isomer. The peak located at 123 ppm, which displays an
integrated intensity of 2, is indicated.
(DOC)
Figure S3 Vibrational absorption (top) and Stark (bot-
tom) spectra of 50 mM bosutinib isomer in 1-propanol
at 77 K. A numerical fit to the Stark spectrum, from which the
linear Stark tuning rate was derived, is shown in red. The
numerical fit is a weighted sum of the derivatives of the absorption
spectrum, and the individual fit components are shown as thin
lines. The value of the linear Stark tuning rate is 0.74 cm
21/(MV/
cm).
(DOC)
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